Technology Transfer: Expansion of Image Analysis Capabilities

Definiens AG, a leader in advanced image intelligence solutions,
today announced that they have entered into an agreement with The
Wellcome Trust Sanger Institute at Cambridge, UK to augment their
programmes aimed at creating large scale gene expression profiles.
The ‘Atlas of Protein Expression’ and
‘Embryo Gene Expression’ programs at the Wellcome Trust Sanger
Institute both aim to produce large scale public databases describing
gene and protein expression patterns in the developing embryo and adult
tissues. “To achieve these ends we have applied high throughput
immunohistochemistry and automated image capture, generating Terabyte
scale image databases”, commented Dr Gareth Maslen, Informatics Project
Manager at the Wellcome Trust Sanger Institute. “We felt that
traditional methods of manual image analysis and annotation were
unlikely to cope with the volume and complexity of the data being
The Wellcome Trust Sanger Institute has chosen to implement Definiens’
image analysis solution Cellenger® to help improve the throughput,
analysis and annotation of images generated by these programs.
“We are very delighted to offer a
comprehensive and meaningful solution for image analysis with our
leading-edge technology and to share our expertise with world renowned
research scientists at a prestigious institute such as The Wellcome
Trust Sanger Institute,” stated Thomas Heydler, CEO of Definiens AG.
“Our collaboration with The Wellcome Trust
Sanger Institute is a major stepping stone for Definiens and we look
forward to assist this world-class research centre in successfully
incorporating our technology into their research programs.” says Dr
Neil Dey, VP of Marketing and Business Development at Definiens.
Commercial terms of the collaboration were not disclosed.
About The Wellcome Trust Sanger Institute
The Wellcome Trust Sanger Institute
(, which receives the majority of its funding from the
Wellcome Trust, was founded in 1992 as the focus for UK sequencing
efforts. The Institute is responsible for the completion of the
sequence of approximately one-third of the human genome as well as
genomes of model organisms such as mouse and zebrafish, and more than
90 pathogen genomes. In October 2001, new funding was awarded by the
Wellcome Trust to support a new range of post-genomic programmes
designed to understand the biological function of genes and their
relevance to our health. These programmes are built around a Faculty of
more than 30 senior researchers.
About Definiens
Definiens is a global leader in providing advanced image
intelligence solutions and services that enable its clients to harness
all relevant information from digital image to support fast and
accurate decision making crucial to its business process. Definiens’
products are built on its platform technology (eCognition) that
represents a quantum leap in the realms of digital image analysis. Our
products are offered across chosen markets, initially focusing on Earth
Observation/Remote Sensing (EO/RS) and Life Sciences. Definiens offers
advanced and robust image analysis solutions to accelerate the drug
discovery, development, and diagnostics processes in life sciences, and
perform satellite and aerial image classification more intelligently,
more accurately, and more efficiently than traditional methods.
Definiens has customers worldwide in the areas of Life Sciences and
Earth Observation/Remote Sensing (EO/RS), including leading companies,
academic centers, and government agencies. Founded in 1994 by Nobel
Laureate Prof. Dr. Gerd Binnig, Definiens is based in Munich, Germany.
For further information regarding the company and its products please
Definiens AG Andrea Mueller-Beilschmidt,
+49 (0)89 23 11 80-36
Mobile +49 (0)171 76 66 518
Fax +49 (0)89 23 11 80-90
(Credits Definiens
Author: EARSC

This website uses cookies to collect analytical data to enhance your browsing experience. Please accept our cookies or read our Privacy policy.